WallStSmart

Equinor ASA ADR (EQNR)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinor ASA ADR generates 767% more annual revenue ($105.98B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 4.8%. EQNR appears more attractively valued with a PEG of 1.03. VRTX earns a higher WallStSmart Score of 66/100 (B-).

EQNR

Buy

51

out of 100

Grade: C-

Growth: 2.0Profit: 6.5Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 2.32

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQNRUndervalued (+47.4%)

Margin of Safety

+47.4%

Fair Value

$54.29

Current Price

$36.69

$17.60 discount

UndervaluedFair: $54.29Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQNR3 strengths · Avg: 8.3/10
Market CapQuality
$94.78B9/10

Large-cap with strong market position

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Free Cash FlowQuality
$2.10B8/10

Generating 2.1B in free cash flow

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

EQNR4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-5.1%2/10

Revenue declined 5.1%

EPS GrowthGrowth
-27.3%2/10

Earnings declined 27.3%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EQNR

The strongest argument for EQNR centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.03 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : EQNR

The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth. Thin 4.8% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

EQNR profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

VRTX carries more volatility with a beta of 0.30 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 51/100), backed by strong 35.5% margins. EQNR offers better value entry with a 47.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinor ASA ADR

ENERGY · OIL & GAS INTEGRATED · USA

Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?